Diabetes Mellitus Clinical Trial
Official title:
The Development of Contextual Cognitive Behavioural Approach to Painful Diabetic Neuropathy: A Feasibility Trial
Verified date | October 2018 |
Source | King's College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Diabetes mellitus (DM) is highly prevalent, and a significant public health problem.
Approximately 25-30% of all individuals with DM develop painful diabetic neuropathy (PDN).
PDN is considered a complex, multi-dimensional condition, possibly affecting the physical and
mental health of the individual. PDN is usually described as a sense of burning, stabbing,
aching and/or pricking mainly affecting areas like toes, legs, and feet and physically
interfering with mobility, sleep, mood, and overall quality of life. This condition
represents both a significant problem in its own right and a useful condition in which to
test treatments that may offer wider benefits for neuropathic pain conditions in general.
A relatively new and promising approach to chronic pain, within the wider range of cognitive
and behavioural approaches, is Acceptance and Commitment Therapy (ACT). ACT is a form of
Cognitive Behavioural Therapy (CBT) that focuses specifically on increasing psychological
flexibility. Psychological flexibility is the capacity to change or continue with a
behaviour, depending on which is more effective, according to one's goals and what the
current situation affords. Psychological flexibility in turn includes processes of
acceptance, values-based action, and other processes related to mindfulness. There are no
published studies of ACT for individuals with PDN, and the limited available evidence
indicates that a CBT-based intervention like ACT has the potential to reduce pain in people
with PDN. People with PDN have clear treatment needs. While ACT may help them, little is
known directly about the relevance of different components of ACT for this condition or about
how to customise it for them. The proposed research aims to conduct a small feasibility trial
which will pilot test a psychological treatment for PDN and assess the feasibility,
acceptability and effectiveness of such a treatment.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | October 1, 2019 |
Est. primary completion date | October 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Aged at least 18 years. - Confirmed diagnosis of diabetes. - Presence of painful diabetic neuropathy. - Have full verbal and written proficiency in English. - Willingness and ability to take part. - Have computer literacy. Exclusion Criteria: - Not understanding verbal explanation or written information in English. - Suffering from neuropathy due to other causes than diabetes. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Guy's hospital NHS Foundation Trust (Diabetes Clinic) | London | |
United Kingdom | St Thomas' NHS Foundation Trust (Diabetes Clinic) | London |
Lead Sponsor | Collaborator |
---|---|
King's College London | Diabetes UK |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Committed Action Questionnaire (CAQ-8) | The CAQ-8 is an eight-item measure of committed action, a facet of PF. Committed action is the ability to persist with actions that are guided by goals, including when this runs into discouraging experiences and to change these actions when they are shown to be ineffective. Responses to the items were rated from 0 (never true) to 6 (always true). Out of the eight items four are positively keyed and four negatively keyed. | 8 weeks | |
Secondary | Cognitive Fusion Questionnaire (CFQ-7) | The CFQ-7 offers a psychometrically sound measure of cognitive fusion. 16 Cognitive fusion refers to a domination of cognitive influence over direct experiential influence on behavior, and a lack of separation between the content of the thoughts and the situations or people to which they refer. Cognitive defusion, on the other hand, is the ability to see thoughts as just thoughts, and not as essential reflections of events as they are directly experienced. CFQ-7 consists of 7-items rated on a 0 (never true) to 7 (always true) point scale. An early version of the CFQ has been validated in chronic pain sample. | 8 weeks | |
Secondary | Chronic Pain Acceptance Questionnaire (CPAQ-8) | The CPAQ-8 is a validated questionnaire which measures acceptance of chronic pain. It includes engagement in activities while experiencing pain and willingness to experience pain without trying to control or avoid it. CPAQ-8 is based on the 20-item questionnaire and has been validated 12. Items are rated on a scale from 0 (never true) to 6 (always true). Higher scores reflect greater acceptance of pain. | 8 weeks | |
Secondary | Douleur neuropathique 4 (DN4) | Presence of neuropathic pain was assessed with a screening measure called DN4. It consists of interview questions and physical tests and has also been validated as a self-reported measure. It has a specificity of 83% and sensitivity of 90%. | 8 weeks | |
Secondary | Pain Scale | Pain intensity and distress were assessed through four questions using 0 (no pain) to 10 (worst possible pain) numerical ratings of pain. Participants were asked to rate their pain right now and in the past week, and how distressing is their pain right now and in the past week. | 8 weeks | |
Secondary | Patient Health Questionnaire (PHQ-9) | The PHQ-9 is a reliable and validated measure used as an index for depression severity. It includes 10-items based on DSM-IV. The nine items that reflect severity of depression symptoms area each rated on a scale from 0 (not at all) to 4 (nearly every day). The last item is a measure of impact of depression and is rated from 'not difficult at all' to 'extremely difficult'. The higher score indicates higher levels of depression severity. | 8 weeks | |
Secondary | Self Experiences Questionnaire (SEQ) | The SEQ is a 15-item self-report measure of self-as-context (SAC), within the PF model. This "contextual self" is defined as a sense of self that is not based upon self-evaluations and is separate from one's thoughts and feelings. This could also be referred as, taking a point of view on one's psychological experiences, or as "perspective taking". All items are rated on a scale from 0 (never true) to 6 (always true). All items are positively keyed, and higher scores indicate higher PF. | 8 weeks | |
Secondary | Work and Social Adjustment Scale (WSAS) | The WSAS is a five-item, reliable and validated, self-report measure of impairment in work and social functioning, or as we label in here, "functional impairment". Each item is rated from 0 (no impairment) to 8 (very severe impairment). WSAS items refer to work, home management, social and private leisure, and relationships. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |